Marrow stromal cells (MSCs) are postnatal progenitor cells that can be easily cultured ex vivo to large amounts. This feature is attractive for cell therapy applications where genetically engineered MSCs could serve as an autologous cellular vehicle for the delivery of therapeutic proteins. The usefulness of MSCs in transgenic cell therapy will rely upon their potential to engraft in nonmyeloablated, immunocompetent recipients. Further, the ability to deliver MSCs subcutaneously -as opposed to intravenous or intraperitoneal infusions -would enhance safety by providing an easily accessible, and retrievable, artificial subcutaneous implant in a clinical setting. To test this hypothesis, MSCs were retrovirally engineered to secrete mouse erythropoietin (Epo) and their effect was ascertained in nonmyeloablated syngeneic mice. Epo-secreting MSCs when administered as 'free' cells by subcutaneous or intraperitoneal injection, at the same cell dose, led to a significant -yet temporaryhematocrit increase to over 70% for 55713 days. In contrast, in mice implanted subcutaneously with Matrigeltembedded MSCs, the hematocrit persisted at levels 480% for over 110 days in four of six mice (Po0.05 logrank). Moreover, Epo-secreting MSCs mixed in Matrigel elicited and directly participated in blood vessel formation de novo reflecting their mesenchymal plasticity. MSCs embedded in human-compatible bovine collagen matrix also led to a hematocrit 470% for 7578.9 days. In conclusion, matrixembedded MSCs will spontaneously form a neovascularized organoid that supports the release of a soluble plasma protein directly into the bloodstream for a sustained pharmacological effect in nonmyeloablated recipients.
Introduction
In vivo delivery of replication-defective adenoviral (Ad) [1] [2] [3] [4] [5] and adeno-associated viral (AAV) vectors 6 encoding for therapeutic plasma proteins such as erythropoietin (Epo) has been described. [7] [8] [9] [10] However, the utilization of Ad vectors 3, 11 and of AAV vectors 12, 13 may be limited by their potential ability to elicit a lethal host immune response [14] [15] [16] [17] or possibly malignant complications. 18 Nonviral approaches for Epo delivery have also been realized through naked plasmid DNA injection and gene electrotransfer. [19] [20] [21] [22] [23] As compared to viral vectors, gene expression from plasmid DNA may be insufficient to provide therapeutic protein levels, especially in larger mammals. 24, 25 Although gene therapy strategies are promising, alternative strategies for sustained delivery of therapeutic plasma proteins are worth developing. Transgenic cell therapy, where autologous cells are genetically engineered into synthetic endocrine cells and subsequently returned to the donor, shows promise and has been tested in clinical trials. 26 A crucial component to this strategy will be to choose an autologous cellular source of sufficient expansion potential to allow for a sizable clonal implant. Indeed, bone marrow stromal cells (MSCs), which play a crucial role in the bone marrow microenvironment and in hematopoiesis, may constitute an ideal autologous cellular vehicle for the delivery of therapeutic gene products. [27] [28] [29] [30] [31] MSCs are present in sufficient numbers in humans of all ages, they can be harvested by bone marrow aspiration in the absence of prior mobilization treatment, and they can differentiate into many mesenchymal phenotypes such as osteoblasts, chondrocytes, adipocytes, fibroblasts, skeletal myoblasts, cardiomyocytes, tenocytes, and smooth muscle cells. 29, 30, 32, 33 Studies have shown that MSCs maintain their precursor phenotype following gene modification and culture expansion, and are therefore promising for cell and gene therapy applications. 30 In their native 'pluripotent' state, MSCs may be utilized clinically for the treatment of mesenchymal disorders, such as osteogenesis imperfecta. 34, 35 The strong proliferative capacity of MSCs renders these amenable to retroviral gene transfer, 29 and subsequent expansion for utilization as a vehicle for soluble protein secretion. 36 The use of MSCs has been demonstrated for the expression of an exogenous gene product in vitro and as an efficient cellular vehicle for the release of proteins in vivo. 29, [37] [38] [39] [40] [41] Various studies have shown the delivery of a secretable human transgene product by MSCs administered via the intravenous route in immunodeficient rodents. 40, 42, 43 When infused intravenously in immunocompetent recipients, genetically engineered MSCs engendered transiently detectable plasma levels of a species mismatched secreted protein. 44, 45 Therefore, the successful utilization of MSCs in transgenic adoptive cell therapy will depend upon their demonstrated ability to engraft in nonmyeloablated, immunocompetent recipients and lead to a sustained pharmacological effect. We have previously shown in a pilot study that intraperitoneal implantation of gene-modified MSCs leads to pharmacological production of a plasma protein in unconditioned normal hosts. 41 However, intravenous or intraperitoneal delivery of large amounts of engineered cells will not allow for their subsequent removal if unforeseen complications were to arise from their use. Therefore, we propose that as an alternative delivery route, engineered MSCs can be returned as a subcutaneous implant.
To test this hypothesis and as a proof-of-concept, we have utilized MSCs retrovirally engineered to secrete Epo. Long-term pharmacological effect can be monitored unambiguously by serial measurement of hematocrit (Hct) in experimental animals and will allow for comparison of various delivery routes. We report that the levels of mEpo released in vivo from MSCs implanted subcutaneously or in the abdominal cavity are sufficient to cause a supraphysiological effect as evidenced by a significant increase of blood Hct. Moreover, Epo-secreting MSCs mixed in Matrigel were shown to participate in de novo blood vessel formation and to differentiate into CD31 + cells. These data demonstrate that MSCs have the plasticity to spontaneously form a neovascularized organoid and that this platform will allow for sustained delivery of pharmacological levels of soluble plasma proteins such as Epo.
Results

Titer of retrovirus producers
To determine gene transfer efficiency and transgene expression in stably transfected retroviral producer cells, flow cytometry analysis for green fluorescent protein (GFP) expression was performed. The proportion of GFP-positive cells in the polyclonal producer populations GP+E86-Epo-IRES-EGFP and Sorted GP+E86-Epo-IRES-EGFP, based on green fluorescence, was 34 and 97%, respectively. To evaluate the quantity of infectious particles released by these producers, a titration assay using their retroviral supernatant was conducted and the viral titers obtained were B2.4 Â 10 5 and B4.0 Â 10 5 infection particles/ml, respectively. The percentage of LacZ-positive cells in the GP+E86-LacZ viral producer cell population was 495% and the viral titer of these cells was B1.1 Â 10 5 infectious particles/ml.
Retrovector expression and mEpo secretion by genemodified marrow stroma
To determine the molecular genetic stability of the Epo-IRES-EGFP retroviral construct (Figure 1 ), proviral DNA in the genome of polyclonal retrovirally transduced MSCs was analyzed by Southern blot. A probe complementary to the GFP reporter allowed the detection of a DNA band consistent with the 3436 bp fragment anticipated from EcoRV digest of integrated unrearranged Epo-IRES-EGFP proviral DNA (Figure 2) . No subgenomic or rearranged retrovector integrant was detected.
Retrovector expression in genetically engineered murine MSCs was confirmed by flow cytrometry analysis for GFP expression. The proportion of Epo-IRES-EGFPmodified MSCs expressing GFP was 91%. To establish that murine MSCs transduced with Epo-IRES-EGFP secrete mEpo in vitro, and quantitate the level, supernatant collected from these cells was analyzed by ELISA for human Epo. The Epo-IRES-EGFP-modified MSC population was analyzed and found to secrete 17 U of Epo per 10 6 cells per 24 h. The percentage of LacZpositive cells in the LacZ-Epo-IRES-EGFP-modified MSC population was 490%. LacZ-Epo-IRES-EGFP-modified stroma was noted to secrete 17 U of Epo per 10 6 cells per 24 h. There was no Epo detected in the supernatant collected from control IRES-EGFP-transduced MSCs and LacZ-IRES-EGFP MSCs (data not shown).
Intraperitoneal implantation of Epo-secreting MSCs
We determined if mEpo secretion from Epo-IRES-EGFPtransduced MSCs implanted by intraperitoneal injection in nonmyeloablated, immunocompetent mice can lead to a measurable effect on Hct. We also established if there is a dose-response relationship between the number of Epo-IRES-EGFP-modified stromal cells injected and the resulting Hct. Cohorts of mice were implanted with Figure 1 Schematic illustration of retroviral plasmid construct Epo-IRES-EGFP. The retroviral vector Epo-IRES-EGFP was generated as described in the Materials and methods section. The murine erythropoietin (Epo) cDNA sequence was inserted in the multiple cloning site of our previously described pIRES-EGFP construct, upstream of an internal ribosomal entry site (IRES) and the EGFP reporter gene. The retrovector pIRES-EGFP served as the control plasmid. , or 10 7 Epo-IRES-EGFP-engineered MSCs. Peripheral blood was collected, and Hct and plasma Epo concentration measured over time as shown in Figure 3 . As illustrated in Figure 3a , the Hct of mice that received 10 5 mEpo-secreting stromal cells rose to a peak value of 6071.1% at 5 weeks postimplantation. In mice injected with 10 Epo-IRES-EGFP-transduced MSCs, blood Hct rose to a maximum of 6873.8% at 2 weeks following implantation and then quickly declined to a steady B61% observed until week 12. The recipients of 5 Â 10 6 mEpo-secreting MSCs had an increase in Hct that attained a value of B78% at 2 weeks postimplantation, remaining above 75% until 7 weeks following stroma administration. The Hct of mice implanted with 10 7 of these gene-modified MSCs attained the highest level at 4 weeks (B88%), thenceforth persisting at B85% or greater up to week 9 and over 70% up to week 12. A parallel group of mice received 10 7 IRES-EGFP-transduced MSCs. These control mice maintained Hct levels ranging between 51 and 57% throughout this study (Figure 3a) . A tight correlation was revealed between the number of i.p. implanted Epo-secreting MSCs and the resulting peak in the Hct (r¼0.97).
To quantify the plasma concentration of mouse Epo in mice administered Epo-IRES-EGFP-engineered marrow stroma, plasma Epo levels were measured by human Epo ELISA. As done by others in the field, 5, 49 we utilized ELISA kits for the detection of human Epo to detect mouse Epo. Although affinity for mEpo is poor, 50 it remains the standard in the field and serves as a basis for comparison. Therefore, our measured plasma mEpo concentrations are likely underestimated because of levels below the threshold of detectability of this kit. Mice that received by intraperitoneal injection 10 7 and 5 Â 10 6 Epo-IRES-EGFP-engineered MSCs secreting in vitro 17 U of Epo per 10 6 cells per 24 h, exhibited a rise in plasma Epo levels to 740720 and 298725 mU/ml, respectively, at 3 days postimplantation (Figure 3b ), Marrow stroma implant for erythropoietin delivery in normal mice N Eliopoulos et al which declined proportionally by over 50% to 333760 and 141715 mU/ml, respectively, at 1 week, and by over 65% to 255715 and 96718 mU/ml, respectively, at 2 weeks. The concentration of Epo detected in the plasma of these mice at 7 weeks or greater postimplantation was under 20 mU/ml. LacZ-Epo-IRES-EGFP-modified MSCs per mouse. The Hct of these mice increased from a baseline of 5373% (mean7s.d.) to 9071, 7672, and 6771%, respectively, within 2 weeks following implantation, as shown in Figure 4a . The Epo-secreting MSC dose and the resulting Hct correlated strongly (r¼0.90). The Hct of the negative control group generated by implantation of Matrigel-embedded LacZ-IRES-EGFP MSCs maintained the baseline values (5173%) over the 4-week period of the experiment. As a comparison, we determined the effect of Matrigel admixed with recombinant human Epo (rhuEpo) only. We found that in mice implanted with Matrigel/rhuEpo (1000 U in 0.5 ml of Matrigel or B40 000 U/kg), the Hct increased from 5072 to 6372% within 2 weeks and was thereafter sustained for the subsequent 2 weeks. The pattern in the change of Hct over time with rhuEpo was similar to that achieved when mice received the lowest tested dose of 0.25 Â 10 6 Epo-secreting MSCs (Figure 4a ).
To determine the concentration of mouse Epo in blood plasma of mice subcutaneously injected with Eposecreting MSCs embedded in Matrigel, human Epo ELISA was performed. In mice implanted with these Matrigel-embedded MSCs, the plasma Epo concentration increased from o30 mU/ml prior to implantation to B510, 280, and 270 mU/ml with 0.25 Â 10 6 LacZ-Epo-IRES-EGFP-modified MSCs at 1, 2, and 3 weeks postimplantation, respectively (Figure 4b ). At these time points, 0.5 Â 10 6 LacZ-Epo-IRES-EGFP MSCs led to plasma Epo levels of B700, 540, and 570 mU/ml. Values observed at 4 weeks were similar to those at 2 and 3 weeks following implantation. In mice implanted with Matrigel mixed with LacZ-IRES-EGFP MSCs or rhuEpo, the concentration of Epo detected was o35 mU/ml. Unlike the change in Hct observed over time with rhuEpo, plasma Epo levels were not altered ( Figure 4 ), which is likely because of the short half-life of the recombinant protein (B24 h when administered by subcutaneous injection) and the nonsustained nature of its delivery as opposed to continuous Epo release achieved when Epo-secreting MSCs are embedded in Matrigel.
In vivo endothelial differentiation of Matrigelembedded Epo-secreting MSCs
To study the in vivo fate of Epo-secreting MSCs mixed in Matrigel, these cells were gene modified to also express b-galactosidase (LacZ-Epo-IRES-EGFP MSCs). X-gal histochemical analysis of surgically excised implants was subsequently performed at 4 weeks postimplantation. Macroscopic examination revealed the occurrence of blood vessels within MSC-containing Matrigel implants ( Figure 5a ). Sections of the implant were prepared to show transgene-expressing cells based on LacZ gene reporter activity. By X-gal staining, we detected the bgalactosidase-expressing Epo-producing MSCs randomly dispersed within the implant with a fibroblastlike histological appearance but additionally, as shown in Figure 5b , incorporated in the wall of blood vessels. As evidenced in Figure 5c , these cells had adopted the histological configuration of endothelial cells and had 
Long-term Hct following subcutaneous implantation of Epo-secreting MSCs in Matrices
In order to assess if providing MSCs with an artificial microenvironment is of importance for sustained pharmacological production of Epo, we compared the longterm impact on Hct of MSCs delivered freely in the subcutaneous space with MSCs mixed in Matrigel. As shown in Figure 6a , in C57Bl/6 mice implanted with 4 Â 10 6 Matrigel-embedded Epo-IRES-EGFP MSCs, the Hct increased from a basal 5570.7% (mean7s.e.m.) to 8271.2% at 17 days postimplantation and persisted at levels of 80-90% until day 70 in one mouse, and for over 300 days in the other two recipient mice. Control mice were generated by implantation with 4 Â 10 6 Matrigelembedded IRES-EGFP MSCs and demonstrated a consistent Hct of B55% over time (Figure 6a) . In a separate experiment where 4 Â 10 6 LacZ-Epo-IRES-EGFP MSCs mixed in Matrigel were injected in another three mice, two of three recipient animals showed Hcts above 80% from day 22 to past day 118 postimplantation (Figure 6a ). Control mice (n¼3), which received 4 Â 10 6 LacZ-IRES-EGFP MSCs in Matrigel, maintained an Hct of B55% (Figure 6a ). In contrast, for the same number of Epo-IRES-EGFP MSCs in the absence of Matrigel, the Hct rose from a basal 5670.3% (mean7s.e.m.) before implanta- Figure 5 In vivo differentiation of Matrigel-embedded Epo-secreting marrow stromal cells into CD31 + endothelial cells. Epo-IRES-EGFPtransduced MSCs subsequently gene modified with LacZ retroparticles were mixed with Matrigel, and implanted by subcutaneous injection in normal, unconditioned C57Bl/6 mice, at a density of 4 Â 10 6 cells in 500 ml Matrigel. Four weeks later, recipient syngeneic mice were killed, implants retrieved, and sections prepared and X-gal stained to show b-galactosidaseexpressing donor stroma. Macroscopically evident neoangiogenesis occurred in MSC-containing implants (a). Representative hematoxylin and eosin stained sections from Matrigel implants comprising Eposecreting MSCs show a cross-sectioned blood vessel containing LacZ+ marrow stromal cells (green-blue color) (b, Â 40 magnification), some of which are immunohistochemically stained with anti-mouse CD31 antibodies (light-brown color) (c, Â 100 magnification). (Figure 6b ). A significant difference on long-term effect on Hct was noted between the Matrigelembedded Epo-secreting MSCs when compared to the unembedded cells (P¼0.0348 LogRank).
Matrigel is immunologically incompatible with nonmurine species. Among the many components of Matrigel, collagen figures prominently and may play an important role as part of the artificial microenvironment provided by Matrigel to MSCs. We hypothesized that a human-compatible type I bovine-derived collagen pharmaceutical-grade product could serve as a substitute for Matrigel, thereby offering clues toward clinically feasible application of this strategy. As shown in Figure  7 , 4-5 Â 10 6 collagen-embedded Epo-IRES-EGFP MSCs led to a significant increase in Hct compared with controls ( Figure 7) . Specifically, in mice (n¼5) implanted with Collagen-Matrix-embedded Epo-secreting MSCs, the Hct increased from 5570.3% to a peak level of 8272.4% at 20 days and thereafter gradually decreased. A significant difference in Hct was observed between mice implanted with Collagen-Matrix-embedded Eposecreting MSCs and control mice (Po0.001) (Figure 7 ). The effect on Hct was lost in all mice by 120 days postimplantation. We noted that the decline in Hct was concurrent with the physical disappearance of the implant that was palpable in the first weeks and gradually resorbed. When comparing the long-term effect on Hct, all mice implanted with Collagen-Matrix-embedded Eposecreting MSCs sustained an Hct above 70% for 7578.9 days, whereas in most mice (four of five) that received unembedded cells, this level lasted 3271.5 days.
Discussion
A variety of autologous cellular vehicles for delivery of Epo have been explored, including skeletal myoblasts 49, 51 and stomach-implanted vascular smooth muscle cells. 52 Delivery of transgenes other than Epo has also been explored with hematopoietic stem cells, lymphocytes, fibroblasts, human umbilical vein endothelial cells, and blood outgrowth endothelial cells (BOECs). 53 In contrast to MSCs, there are drawbacks associated with the use of most of these cells in an autologous setting. Skin fibroblasts have been shown to inactivate introduced vector sequences following transplantation 54, 55 and, depending on the age of the donor, may have limited in vitro proliferation capacity; 56 this may limit the amount of engineered fibroblasts available for clinical use. 26 Skeletal myoblasts are present in very low amounts in the majority of adult mammals, and their successful growth and transplantation is technically challenging. [57] [58] [59] Vascular smooth muscle cells, to engraft in humans, may necessitate arterial injury. [60] [61] [62] Hematopoietic stem cells can be difficult to expand in culture and gene-modify, 63, 64 and very large numbers are required for engraftment in the absence of a toxic 'conditioning' regimen. 65 Lymphocytes possess a short lifespan, 66 and human umbilical vein endothelial cells cannot be obtained from an adult.
In contrast to terminally differentiated cell types, autologous MSCs have a very robust expansion capacity and inherent plasticity that can be exploited therapeutically. 30 Indeed, the safety of culture-expanded MSCs was validated in a clinical trial where autologous human MSCs were coinjected with peripheral blood stem cells in breast cancer patients undergoing chemotherapy. 67 Similarly, no side effects occurred in patients of a phase I trial following the intravenous administration of up to 50 million cultured autologous MSCs. 68 These data buttress the clinical feasibility of using autologous MSCs following a 'conditioning' regimen. Although practical in the setting of cancer therapy, toxic 'conditioning' preparatory regimens would be intolerable for cell therapy of nonmalignant disease. Hence, the practical use of MSCs for the secretion of therapeutic gene products in cell and gene therapy applications will rely on their capacity to engraft and persist in vivo following reimplantation, 69 in the absence of 'conditioning' regimens. Several investigators have examined recombinant protein delivery by genetically engineered MSCs following their intravenous administration in immunodeficient hosts. Engraftment and persistence of human MSCs expressing human factor VIII, human factor IX, or human IL-3 was demonstrated in unconditioned immunodeficient mice following transplantation. 40, 42, 43, 70, 71 Similar experiments with human transgene products have been carried out in immunocompetent transplant models. For example, gene-modified canine MSCs expressing human growth hormone or human factor IX were infused in unconditioned normal dogs. However, the human xenoprotein was only very transiently detected in the plasma 39, 44 and this was shown to be because of the production of neutralizing antibodies (canine anti-hFIX). 39 Similarly, in baboons surgically implanted with human Epo genemodified baboon MSCs placed in an immunoisolatory device, the detection of the human protein lasted up to 9-139 days. 
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Although it is speculated that genetically engineered autologous MSCs will be useful for transgenic cell therapy of disease without requirement of prior myeloablation, 69 the biological proof of this hypothesis still needs to be demonstrated in animals with intact immune and hematological systems. In an effort to address this issue, we gene-modified murine MSCs to produce murine Epo and tested their long-term effect on erythropoiesis in normal mice. We chose Epo as a 'reporter' transgene since its long-term in vivo biological activity is readily and objectively assessed by serial measurement of Hct over time. This experimental approach also serves as proof-of-principle for the utility of MSCs as cellular vehicles for pharmacological delivery of therapeutic plasma-soluble proteins.
We first generated a bicistronic retrovector comprising the murine Epo cDNA and the GFP reporter gene, transduced murine MSCs and confirmed mEpo transgene expression by ELISA. We then implanted the genetically engineered MSCs into unconditioned normal syngeneic mice subcutaneously or intraperitoneally. We noted a robust and sustained elevation of blood Hct, with the best long-term effect noted in subcutaneously implanted matrix-embedded cells. Ding et al 27 have shown that intravenous infusion of autologous MSCs in normal mice will lead to their dispersion in spleen, lung, kidney, and marrow. In contrast, intraperitoneal injection of isogenic MSCs will not lead to systemic dispersion unless accompanied by sublethal irradiation. 72 Several studies have indicated that in the absence of conditioning treatment or mesenchymal tissue defect in the host, systemic engraftment of MSCs, outside the implantation site, is unlikely to occur. 73 This observation has been validated in allogeneic MSC transplantation in children with osteogenesis imperfecta. 34 Based on these reports, we speculate that the MSCs described in this study delivered by intraperitoneal injection are unlikely to have migrated outside of the abdominal cavity to other organ sites. However, for clinical applications, if genetically engineered MSCs were to relocate to undesirable organ compartments or if serious side effects were to arise, it would be impossible to remove these cells. Indeed, in a published cell therapy trial where transfected fibroblasts were used, a very significant effort was deployed to isolate engineered cellular clones that remain untransformed by the ex vivo DNA transfection procedure. 26 Therefore, the theoretical risk of malignant transformation -which arises from the use of integrating gene delivery platforms -is a strong incentive to explore implantation strategies that avoid widespread biodistribution of engineered cells, as would occur after intravenous or intraperitoneal implantation.
Cells sequestered within a subcutaneous implant would enhance safety for clinical trials, and for this reason we have explored the use of engineered MSCs embedded within a matrix. We speculate that the sustained therapeutic effect we observed utilizing Matrigel-embedded gene-modified MSCs is because of the release of soluble plasma protein Epo directly into the bloodstream. This is supported by our demonstration that the Epo-secreting MSCs mixed in Matrigel also elicited and participated in de novo blood vessel formation leading to a neovascularized MSC implant ( Figure  5 ). Specifically, we showed the occurrence of these cells near and within vascular structures as well as their 6 cells per 24 h in vitro led to an increase in Hct attaining a peak value of B82% at 8 weeks which persisted for 6 months following implantation. However, the limitations in expanding transfected clonal human fibroblast colonies derived from adult volunteers to sufficient numbers to obtain a sizable implant will always be a limitation to their use as a cellular delivery vehicle. 26 Therefore, we speculate that human MSCs secreting comparable amounts of hEpo (or any other therapeutic plasma-soluble protein) may have a similar pharmacological effect, and that the cell dose required for an average 70 kg adult may be clinically realizable. Indeed, human postnatal MSCs have been reported to be able to divide more than 50 times. This expansion potential should easily allow for genetic engineering and clonal selection, and subsequent expansion to cell doses high enough for a pharmacological effect.
As was similarly postulated in an in vivo study examining systemic Epo levels following direct intramuscular delivery of adenovector, 5 there may be various nonexclusive explanations for the drop in Hct observed in some mice utilizing gene-modified MSCs. There may be a decline in the amount of implanted MSCs over time because of suboptimal in vivo microenvironment, impeding their proliferation or survival, as suggested with other cells. 74 Another reason for the eventual loss of recombinant Epo in plasma is in vivo inactivation of transgene expression or promoter shut-off in genetically engineered cells, as previously seen in other gene therapy approaches. 54, 55 Lastly, the immune system may eliminate transgene-expressing cells. It must be restated that our engineered cells expressed mEpo as well as the xenogenic GFP reporter. In our study, the GFP cDNA served as a genetic marker, reporter, and selectable agent for engineered cells concurrently expressing the nonselectable, linked transgene, mEpo cDNA. In primary bone marrow stromal cells, GFP allowed the evaluation of therapeutic gene transfer efficiency by fluorescence microscopy and flow cytometry analysis. Recent investigations clearly demonstrate that cytotoxic immune response may occur in immunocompetent animals against GFP-expressing syngeneic cells 75, 76 . Although Matrigel serves as a useful support vehicle for MSCs in mice, its composition derived from a murine sarcoma cell line precludes its use in humans owing to obvious bioincompatibility. Matrigel is composed of a very diverse admixture of proteins, growth factors, and basal membrane components including collagen. We speculated that collagen might be an adequate minimal component in mediating MSC survival in implants since integrin-mediated docking to extracellular matrix comMarrow stroma implant for erythropoietin delivery in normal mice N Eliopoulos et al ponents has been reported to inhibit apoptosis in adherent cells. 77 For this reason, we tested a humanbiocompatible, bovine type I collagen porous formulation as an MSC delivery platform/artificial microenvironment in normal mice. Although a long-term effect on Hct was less sustained than that observed with Matrigelembedded cells, our results suggest that type I bovine collagen may serve as an adequate minimal component and that addition of other selected basal membrane components -as found in Matrigel -may allow for development of a high-performance human-compatible matrix platform for MSCs. Human blood outgrowth endothelial cells (BOECs) share similar features to MSCs with regard to desirability as an autologous cellular vehicle for therapeutic proteins such as Factor VIII. Although they have been studied following intravenous administration in immunodeficient mice, 53 their delivery within a collagen-based matrix may theoretically yield similar results as we have observed. Another promising autologous cell type, the recently reported multipotent adult progenitor cells or MAPCs, copurifying with mesenchymal stem cells from the bone marrow, may serve the purpose studied here as well. 78 Interestingly, mice tolerated high Hcts well. Although elevated Hct may lead to premature death from stroke in humans, we did not observe this phenomenon in our test mice. Further, mice with high Hcts did not display behavioral or physiological signs of distress such as weight loss. A reason for the survival of mice with Hct values approaching 90% is perhaps due to the role of nitric oxide. 79 We also showed that the magnitude of the augmentation in blood Hct caused by Epo release in vivo was dependent on the number of implanted genemodified MSCs and on their ex vivo Epo secretion levels. Therefore, our study revealed that we could dose the therapeutic effect and obtain the desired effect by adjusting the amount of genetically engineered MSCs implanted. Alternatively, MSCs engineered with regulated vector systems could be utilized. 37 Lastly, we speculate that engineered MSCs bereft of immunogenic reporter proteins -such as GFP or drug selectable markers like Neo r -should also allow for a more sustained transgene production. Alternative human biocompatible selectable markers would be of use in this setting. 80 In conclusion, our data validate the feasibility of utilizing gene-modified autologous bone marrow stroma as a vehicle for sustained systemic production of recombinant therapeutic proteins in immunocompetent recipients, without the major drawback of myeloablation. Furthermore, when delivered subcutaneously in a matrix, MSCs will spontaneously generate a neovascularized organoid. This report provides a basis for future applications of Matrix-embedded MSCs as a safe and efficient delivery vehicle of plasma soluble gene products in a sustained fashion in the treatment of a large spectrum of inherited or acquired illnesses.
Materials and methods
Cell culture of murine fibroblasts GP+E86 ecotropic retrovirus-packaging cell line 46 from American Type Culture Collection (ATCC) was cultured in Dulbecco's modified essential medium (DMEM) (Wisent Technologies, St Bruno, QC) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Wisent) and 50 U/ml penicillin, 50 mg/ml streptomycin (Pen/ Step) (Wisent). National Institutes of Health (NIH) 3T3 mouse fibroblast cell line, obtained from ATCC, was grown in DMEM with 10% FBS and 50 U/ml Pen/Step. All cells were maintained in a humidified incubator at 371C with 5% CO 2 .
Generation of retroviral vector and of virus-producing cells
The retroviral plasmid vector pIRES-EGFP was previously generated in our laboratory. 47 This construct comprises a multiple cloning site linked by an internal ribosomal entry site (IRES) to the enhanced green fluorescent protein (EGFP) (Clontech Laboratories, Palo Alto, CA, USA). The retroviral vector pEpo-IRES-EGFP (Figure 1 ) was synthesized by obtaining the cDNA for mouse Epo by BamH1 digest of a pBluescript-based construct graciously provided by Jean M Heard (Institut Pasteur, Paris) and ligating it with a Bam H1 digest of pIRES-EGFP.
For the manufacture of recombinant virus-producing cells, the pEpo-IRES-EGFP construct (5 mg) was linearized by Fsp1 digest and cotransfected, utilizing lipofectamine reagent (GIBCO-BRL, Gaithesburg, MD, USA), with 0.5 mg pJ6OBleo drug resistance plasmid 48 generously given by Richard C Mulligan (Children's Hospital, MA, USA), into GP+E86 packaging cells. Stable transfectants were selected by a 5-week exposure to 100 mg/ml zeocin (Invitrogen, San Diego, CA, USA), thus giving rise to the polyclonal virus-producing GP+E86-Epo-IRES-EGFP cells. GFP expression in cells was assessed by flow cytometry analysis utilizing an Epics XL/MCL Coulter analyzer and gating viable cells based on the FSC/SSC profile. A population of Sorted GP+E86-Epo-IRES-EGFP producers was obtained following sorting of GP+E86-Epo-IRES-EGFP cells based on green fluorescence using a Becton Dickinson FACSTAR sorter. The control GP+E86-IRES-EGFP producers were generated in the same manner. Retroparticles from all producers were devoid of replication-competent retrovirus as was determined by the GFP marker rescue assay employing conditioned supernatants from transduced target cells. GP+E86-LacZ retrovirus producing cells were generated by transinfection of the GP+E86 cell line with filtered retroviral supernatant from 293GPG-LacZ producers (generously provided by RC Mulligan, Children's Hospital, MA, USA) twice per day for three consecutive days, in the presence of 6 mg/ml lipofectamine.
Titer determination of retrovirus producers
To assess the titer of GP+E86-Epo-IRES-EGFP and GP+E86-IRES-EGFP producers, NIH 3T3 fibroblasts were seeded at a density of 2-4 Â 10 4 cells/well of six-well tissue culture plates. The next day, cells were exposed to serial dilutions (0.01-100 ml) of 0.45 mm filtered retroviral supernatants, in a total volume of 1 ml complete media with 6 mg/ml lipofectamine. Cells from extra test wells were counted and averaged to disclose the baseline cell number at the moment of virus addition. Three days later, the percentage of GFP-expressing cells was ascertained by flow cytometry analysis. The titer was calculated using the following equation by considering Harvest, culture, and transduction of murine bone marrow stroma Whole bone marrow was harvested from the femurs and tibias of 18-22 g female C57Bl/6 mice (Charles River, Laprairie Co., QC, Canada) and plated in DMEM supplemented with 10% FBS and 50 U/ml Pen/Step. After 4-5 days of incubation at 371C with 5% CO 2, the nonadherent hematopoietic cells were discarded and the adherent MSCs were gene modified as follows. Media was removed from MSCs and replaced with 0.45 mmfiltered retroviral supernatant from subconfluent Sorted GP+E86-Epo-IRES-EGFP or control GP+E86-IRES-EGFP producers once per day for six consecutive days, for each of two successive weeks, in the presence of 6 mg/ml lipofectamine. The resulting genetically engineered stromal cells were subsequently expanded for 2-3 months. As additional populations of gene-modified MSCs, Epo-IRES-EGFP-modified MSCs as well as control IRES-EGFP MSCs were also transduced with retroparticles from GP+E86-LacZ producers twice per day for three consecutive days with 6 mg/ml lipofectamine, giving rise to LacZ-Epo-IRES-EGFP-modified MSCs and LacZ-IRES-EGFP MSCs, respectively. GFP expression in genetically engineered stroma was evaluated by flow cytometry analysis to allow an estimate of the gene transfer efficiency. Beta-galactosidase expression in LacZ gene modified MSCs was determined by X-gal staining. Culture expanded murine MSCs were CD31
À and CD45 À in vitro (data not shown), as reported by others. 29 The supernatant was collected from genetically engineered cells, and mouse Epo secretion was assessed by photometric enzyme-linked immunosorbent assay (ELISA) specific for human Epo (Roche Diagnostics, Indianapolis, IN, USA). Formal institutional approval was obtained for animal studies performed in this project and all animals were handled under the guidelines promulgated by the Canadian Council on Animal Care.
Southern blot analysis
Genomic DNA was isolated from Epo-IRES-EGFP stably transduced primary murine MSCs, as well as from unmodified marrow stroma, utilizing the QIAamp DNA mini kit (Qiagen, Mississauga, ON, Canada). For the Southern blot analysis, 10 mg of genomic DNA was digested with EcoRV, separated by electrophoresis in 1% agarose, and transferred to a Hybond-N nylon membrane (Amersham, Oakville, ON, Canada). The probe was prepared by 32 P radiolabeling of the EGFP complete cDNA utilizing a Random Primed DNA Labeling Kit (Roche Diagnostics) and was hybridized with the membrane. The blot was subsequently washed, and exposed to a Kodak X-Omat film. 6 Epo-IRES-EGFP-modified stromal cells suspended in 150 ml DMEM with 10% FBS were placed on a 1 cm 2 piece of porous Collagen Matrix (Collagen Matrix, Inc., NJ, USA) in the well of a 24-well plate. The matrix became soaked and 15 min later, 800 ml of complete media was added to the well and the MSC-embedded collagen incubated overnight at 371C with 5% CO 2. The following day, one MSC-embedded collagen implant was surgically introduced into the subcutaneous space behind the neck of each of the five syngeneic C57Bl/6 mice anesthetized by isoflurane inhalation. Control mice (n¼5) were implanted with 4-5 Â 10 6 IRES-EGFP-modified MSCs embedded in Collagen Matrix and five additional negative control mice received only the collagen. Blood samples were collected from the saphenous vein with heparinized microhematocrit tubes (Fisher Scientific, Pittsburgh, PA, USA) prior to implantation and every B1 or more weeks postimplantation. Mice were monitored for up to 10 months. Hct levels and plasma mEpo concentrations were ascertained from blood samples. Specifically, Hcts were quantitated by standard microhematocrit procedure, and mEpo concentrations in plasma preparations were assessed by ELISA for human Epo (Roche Diagnostics). 6 Á 3H 2 O, 0.01% sodium deoxycholate, 2 mM MgCl 2 , 1 mM EGTA, and 1 mg/ml X-gal in PBS with 0.02% NP40) for 16 h. Samples were then fixed with 10% formalin, embedded in paraffin and sections of 3-4 mm were prepared. For immunohistochemical staining, specimens were deparaffinized in toluene and rehydrated. Endogenous peroxidase was blocked using 3% hydrogen peroxide followed by incubation with 5% bovine serum albumin with 5% goat serum or 5% donkey serum in PBS for 30 min. Sections were placed at 371C with primary antibodies (polyclonal goat antimouse CD31 at 1:100), followed by biotin-conjugated secondary antibodies (donkey anti-goat IgG from Santa Cruz at 1:100, or goat anti-rabbit at 1:200 from BD Pharmingen), washed, and treated with avidin-peroxidase (ABC Elite kit, Vector Laboratories) for 30 min. DAB substrate (Vector Laboratories) was used for reaction development. Sections were counterstained with hematoxylin and eosin, visualized with an Olympus BX60 microscope, and digital images retrieved on a computer equipped with Image Pro software (Media Cybernetics).
Stroma implantation and blood sample analysis
Matrigel implant removal and processing
